Hong Kong Yuanhua
Biotechnology

Hong Kong Yuanhua Biotechnology is an innovative biotech company involved in the development of targeted drug delivery systems for the treatment of metastatic cancer. Our breakthrough nano-particle technology has been validated across multiple clinical trials and enjoys many significant advantages over current methods.

Through our dedication to innovative science and translational research, Hong Kong Yuanhua Biotechnology has built up a portfolio of drug delivery technologies that have the potential to transform patients’ lives. Moreover, by focusing on one specific area of technology, the company can develop new, effective therapies in a rapid and cost-effective manner, and with lower risk relative to traditional approaches.

Hong Kong Yuanhua Biotechnology current areas of active research include epigenetics, immuno-oncology, protein homeostasis, biotherapeutics, and novel targets. Through advances in these fundamental areas, we will continue to address significant unmet needs, as well as provide physicians and clinicians with new options for managing patients and improving their quality of life.

Hong Kong Yuanhua Biotechnology is committed to improving the health and saving the lives of cancer patients on a global basis through the discovery, development, and commercialization of novel, paradigm-changing drug delivery technology.

cancer : the global killer

Cancer is now the world’s second-biggest killer behind cardiovascular disease. Over the last 25 years, the number of new cancer cases and cancer-related deaths has witnessed a steady increase due to both an aging and growing global population and the continued use of highly toxic cancer treatments.

Recent studies show that cancer accounted for the loss of 196.3 million human life-years across 188 countries in 2016, with one in every three men and one in every five women being diagnosed with any one of a hundred known different types of cancerous tumors.

the challenge

The major global challenge in the prevention and treatment of cancer is the effective delivery and distribution of anti-cancer drugs. While the past decade has seen some improvements in cancer therapeutics, doctors and medical professionals continue to administer outdated and highly toxic cancer treatments and lag far behind in terms of new anti-cancer therapeutic technology when compared to most other areas of medicine.

the solution

Hong Kong Yuanhua Biotechnology has developed a targeted, nanoscale drug delivery system optimized to treat metastatic tumors that has significant advantages over current treatment methods. Our advanced technology can target the delivery of anti-cancer drugs directly to the tumor cells, resulting in the improved overall efficacy of the treatment and a better outcome for cancer patients.

Culture and commitment

Hong Kong Yuanhua Biotechnology has created a workforce that reflects the diversity of the communities in which we do business and the patients we serve. We are united in our commitment to develop and provide life-enhancing medical technologies and make a measurable difference in the lives of millions of people.

Corporate responsibility

Corporate responsibility is at the core of Hong Kong Yuanhua Biotechnology mission to transform the lives of patients with devastating cancer diseases. As we pursue this mission, we are committed to integrity, ethics, and quality and are dedicated to protecting the environment and supporting the communities in which we live and work.

Ethics and Compliance

Hong Kong Yuanhua Biotechnology was founded on the principles of integrity, ethics and sound decision-making, enabling us to sustain our company values and our commitment to putting patients first. These important concepts have and continue to provide the framework for our corporate values and the ethics of how we do business.